KCM
EBS icon

Kendall Capital Management’s Emergent Biosolutions EBS Stock Holding History

Kendall Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,115
Closed -$119K – 186
2022
Q4 		$119K Sell
10,115
-1,280
-11% -$19.8K 0.06% 179
2022
Q3 		$239K Hold
11,395
– – 0.14% 149
2022
Q2 		$354K Sell
11,395
-190
-2% -$6.49K 0.2% 128
2022
Q1 		$476K Buy
11,585
+525
+5% +$23.2K 0.23% 113
2021
Q4 		$481K Buy
11,060
+3,055
+38% +$138K 0.23% 110
2021
Q3 		$401K Buy
8,005
+3,610
+82% +$219K 0.22% 108
2021
Q2 		$277K Buy
+4,395
New +$282K 0.16% 132

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kendall Capital Management's EBS Position: Q1 2023 in Review

Kendall Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2023, closing a stake of 10,115 shares — an estimated $119K sold.

Kendall Capital Management first reported a position in EBS in Q2 2021 and held it in 7 quarters. The position peaked at $481K in Q4 2021. 191 funds tracked by Wall St. Rank hold EBS as of Q1 2023.

  • Kendall Capital Management reported no remaining Emergent Biosolutions position as of Q1 2023 after selling out during the quarter.
  • Kendall Capital Management sold 10,115 Emergent Biosolutions shares in Q1 2023, an estimated $119K.
  • Kendall Capital Management first reported a position in Emergent Biosolutions in Q2 2021 and held it in 7 quarters.
  • Kendall Capital Management's Emergent Biosolutions position peaked at $481K in Q4 2021.
  • 191 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2023.

Based on Kendall Capital Management's 13F filing for Q1 2023, filed 11 May 2023.